Background
==========

The waiting list for organs continues to grow with increasing improvements in organ transplantation, making shortages in organ supplies an enormous obstacle. The number of transplantations has not met the demand for organs from candidates added to the wait list every year \[[@b1-medscimonit-24-997]\]. This challenge highlights the importance of expanding the organ donor pool by including organs from marginal donors who potentially carry transmissible diseases, such as cancers \[[@b2-medscimonit-24-997]\]. Transplanted organs carry the risk of donor-transmitted cancer (DTC), which is tremendously controversial, although the risk of DTC is believed to have been exaggerated \[[@b2-medscimonit-24-997]\]. Donors with a cancer history (DWCH) are becoming more and more important as an organ source \[[@b3-medscimonit-24-997]\]. Since the low risk of DTC cannot be easily assessed or foreseen, it is crucial to formulate allocation strategies that put DWCH to good use while avoiding other disadvantages.

In this study, we collected and analyzed the outcomes of organ recipients from DWCH and donors with no cancer history (DWNCH) from January 1, 2000 to December 31, 2014 in the Scientific Registry of Transplant Recipients (SRTR) database. The primary aim of this study was to compare patient survival, graft survival, and cancer-free survival between patients who received organs from DWCH and those receiving organs from DWNCH. Additionally, we attempted to evaluate the hazard level of various donor cancer types in different organ transplants, aiming to formulate allocation strategies to minimize the risk to recipients while maximizing the utility of organs from DWCH.

Material and Methods
====================

Identification of donors and recipients
---------------------------------------

This study is a retrospective analysis using data from the SRTR, which includes data on all donors, wait-listed candidates, and transplant recipients in the United States submitted by the members of the Organ Procurement and Transplantation Network (OPTN), and was supplemented by mortality ascertainment from the Social Security Death Master File. The SRTR has reviewed and approved this study. Single organ transplant cases (kidney, liver, heart, lung, pancreas, and intestine transplantation) from January 1, 2000 to December 31, 2014 in the SRTR were examined in this study. Cases with a missing or unknown record of the donor's cancer history were excluded. Donors were classified into the DWCH and DWNCH groups according to their cancer history. DWCH were patients with a specific history of malignancy in the registry. In the DWNCH group, patients who met the expanded criteria in the SRTR donor record data were defined as the expanded donor (ECD) group.

Statistical analysis
--------------------

For descriptive analyses, categorical variables are presented as frequencies. The Kolmogorov-Smirnov test was used to verify normal distributions. Comparisons between groups of categorical variables were conducted using Pearson's chi-squared test. The variables compared between 2 groups were the basic characteristics of donors and recipients, including age, race, gender, race, donor and recipient blood type and body mass index (BMI), and history of malignancy in recipients.

Survival analysis was performed for kidney, liver, heart, and lung transplantation. Pancreas and intestine transplantation were excluded because only a small number of DWCH were involved in these procedures. Patient survival was defined as the time between transplantation and death. Graft survival was from transplantation to graft failure or death. The cumulative probability of malignancy and cancer-free survival were defined as the time between transplantation to the first event(s) of malignancy during follow-up. The survival rate was analyzed by the Kaplan-Meier method, and group comparisons were conducted with the log-rank test. A Cox-proportional hazard regression model and the log-rank test were used to compare the survival, hazard ratios and *P* values between different groups with adjustment for the variables described above. The results are presented as adjusted hazard ratios (AHR) with 95% confidence intervals (CI). The variables used for adjustment were those with statistically significant differences between the DWCH and DWNCH groups. Variables used for adjustment in the risk analysis of kidney transplantation were donor age, gender, race, and blood type and recipient age, gender, blood type, BMI, and previous malignancy. Variables used for adjustment in the risk analysis of liver transplantation were donor age, gender, and race and recipient age, gender, BMI and primary diagnosis. Variables used for adjustment in the risk analysis of heart transplantation were donor age, gender, race, and blood type and recipient age, primary diagnosis and previous malignancy. Variables used for adjustment in the risk analysis of lung transplantation were donor age, gender, and race and recipient age and previous malignancy. Expected cases of malignancy were calculated by referencing the incidence in the whole transplant population. Binary logistic regression analysis was utilized to compute odds ratios (OR) and 95% CI between the malignancy incidence of the DWCH and DWNCH groups during follow-up.

All *P* values were 2-sided, and *P*\<0.05 was accepted as statistically significant. All analyses were carried out by the Statistical Package for the Social Science (SPSS) 22.0 (IBM, USA).

Results
=======

Trends of donation from DWCH
----------------------------

Among all donors included in this study, 8385 donors (2.28%) had a history of cancer from January 1, 2000 through December 31, 2014 in the SRTR database. A total of 326 patients with a cancer history underwent organ donation in 2000. The number of patients with a cancer history who underwent donation kept rising until 2005, when it reached 663. Then, the number increased gradually to 717 in 2014 ([Figure 1A](#f1-medscimonit-24-997){ref-type="fig"}). Since 2005, more than 300 kidney transplants and approximately 200 liver transplants came from DWCH annually. In 2014, 423 kidney transplants and 207 liver transplants came from these donors ([Figure 1B](#f1-medscimonit-24-997){ref-type="fig"}). The proportion of DWCH in the whole population of donors remained nearly same even though the number of donors grew annually ([Figure 1C](#f1-medscimonit-24-997){ref-type="fig"}). The proportion peaked in 2003 at 2.66%. In 2014, the rate was only 2.59%. A total of 4696 (2.24%) kidney transplants were from DWCH. Liver transplants included 2713 (3.12%) cases, which was the highest rate of organ use from DWCH in all solid-organ transplants. There were 504 (1.52%), 413 (1.93%), 50 (0.81%) and 9 (0.43%) cases involving DWCH in heart, lung, pancreas, and intestine transplants, respectively ([Supplementary Table 1](#s1-medscimonit-24-997){ref-type="supplementary-material"}). No more than 5% of donor cancer history records in the database were missing for all types of transplantation during 2000 to 2014. The main difference of clinical demographics was shown in [Supplementary Table 2](#s2-medscimonit-24-997){ref-type="supplementary-material"}.

Distribution of donor cancer types in various transplants
---------------------------------------------------------

[Table 1](#t1-medscimonit-24-997){ref-type="table"} shows the distribution of different cancer types of all cases included in this study. We conducted a systematic classification of donor cancer types into 11 groups, including non-melanoma skin cancer (NMSC), melanoma, central nervous system (CNS) cancer, genitourinary cancer, breast cancer, thyroid cancer, hematologic malignancy, gastrointestinal cancer, lung cancer, and other types. NMSC (n=2785), consisting of squamous and basic cell skin cancer, constituted the largest group and was followed by genitourinary cancer (n=1816). CNS cancer (n=1337) represented the third largest group. Other types, such as breast cancer (n=481), melanoma (n=299) and thyroid cancer (n=191), also contributed to the total number of donors with cancer. Glioblastoma multiform (n=275) and astrocytoma (n=264) were the 2 most common types of CNS tumors in these donors. Uterine cervical cancer (UCC, n=937) was the most frequent type in genitourinary cancer. NMSC and UCC were the 2 most common cancer types associated with kidney, liver, heart, and lung transplant. Interestingly, unlike liver transplants, which came from a small number of donors with a gastrointestinal cancer history, or lung transplants, which did not come from donors with a lung cancer history, kidney transplant recipients received a large number (n=994) of organs from donors with a genitourinary cancer history, even with a kidney cancer history. Both pancreas and intestine transplantation included a small number of DWCH.

Survival outcomes of transplants from DWCH versus ECD
-----------------------------------------------------

As a first attempt to evaluate transplants from DWCH, we compared the survival outcomes between the DWCH group and ECD group. [Table 2](#t2-medscimonit-24-997){ref-type="table"} shows that the DWCH group had a lower 5-year patient survival rate (82% versus 75%, *P*\<0.001), 5-year graft survival rate (72% versus 62%, *P*\<0.001) and 10-year cancer-free survival rate (82% versus 80%, *P*=0.03) than the ECD group in kidney transplantation. The DWCH group also had a better 5-year patient survival rate (56% versus 50%, *P*=0.04) and 5-year graft survival days (54% versus 47%, *P*=0.04) in lung transplantation than the ECD group. There was no significant difference in survival outcomes between the DWCH group and ECD group in liver and heart transplantation.

Patient and graft survival of transplants from DWCH versus DWNCH
----------------------------------------------------------------

After comparing outcomes between the DWCH and ECD groups, we attempted further comparisons between the DWCH and DWNCH groups by multivariate Cox-proportional hazards regression analysis. DWCH was an independent risk factor for liver and heart transplantation. The adjusted patient and graft survival in the DWCH group were significantly lower than those in the DWNCH group in liver and heart transplantation ([Figure 2](#f2-medscimonit-24-997){ref-type="fig"}). Liver transplants from DWCH were associated with significantly poorer adjusted 5-year patient survival (HR=1.089, 95% CI: 1.009--1.176, *P*=0.03) and graft survival (HR=1.129, 95% CI: 1.056--1.208, *P*\<0.01) than those from DWNCH ([Figure 2B, 2F](#f2-medscimonit-24-997){ref-type="fig"}). Furthermore, heart transplant recipients receiving organs from DWCH had a lower adjusted 5-year patient survival (HR=1.112, 95% CI: 1.057--1.170, *P*\<0.01) and adjusted 5-year graft survival (HR=1.244, 95% CI: 1.052--1.472, *P*=0.01) than those receiving organs from DWNCH ([Figure 2C, 2G](#f2-medscimonit-24-997){ref-type="fig"}). [Figure 2A and 2E](#f2-medscimonit-24-997){ref-type="fig"} show that DWCH was not an independent risk factor for kidney transplantation (*P*=0.13 and *P*=0.07 for patient and graft survival, respectively). There was no statistical significance between the 2 groups in the adjusted 5-year patient or graft survival after lung transplantation (*P*=0.48 and *P*=0.44, respectively; [Figure 2D, 2H](#f2-medscimonit-24-997){ref-type="fig"}).

Incidence and cumulative probability of malignancy during follow-up
-------------------------------------------------------------------

The cancer burden for organ transplant recipients is a widely acknowledged issue. Recipients are confronted with a remarkably higher risk of *de novo* cancer than the general population \[[@b4-medscimonit-24-997],[@b5-medscimonit-24-997]\]. As shown in [Table 3](#t3-medscimonit-24-997){ref-type="table"}, recipients of kidney transplants from DWCH had a significantly higher incidence of malignancy at 5 years and 10 years of follow-up than did those receiving transplants from DWNCH. The ORs were 1.18 (95%CI 1.04--1.33, *P*=0.01) and 1.14 (95%CI 1.03--1.26, *P*=0.01) for the DWCH and DWNCH groups, respectively. Otherwise, the DWCH group did not have a higher incidence of malignancy in association with liver, heart, or lung transplantation, and the adjusted cumulative probability of malignancy was not significantly different between the DWCH group and DWNCH group for these 4 transplant types ([Figure 3A--3D](#f3-medscimonit-24-997){ref-type="fig"}).

Overall hazard assessment of donor's cancer type in relation to recipient's survival
------------------------------------------------------------------------------------

Apparently, not all types of cancer were negative factors for survival. An adjusted Cox-regression analysis was carried out in order to determine specific cancer types with significant disadvantages in each transplant type. As shown in [Table 4](#t4-medscimonit-24-997){ref-type="table"}, the regression analysis showed that kidney transplant recipients from donors with genitourinary cancer and donors with a gastrointestinal cancer history had lower patient \[HR, genitourinary: 1.20 (1.04--1.38) and gastrointestinal: 1.70 (1.13--2.56)\] and graft survival \[genitourinary: 1.25 (1.13--1.39) and gastrointestinal: 1.55 (1.12--2.15)\]. Donors with NMSC were associated with poorer cancer-free survival \[1.22 (1.05--1.42)\] in kidney transplantation. Recipients of liver transplants from donors with a CNS cancer history and donors with NMSC had a higher risk of graft failure \[1.23 (1.03--1.46) and 1.14 (1.02--1.28), respectively\]. The analysis showed that recipients of heart transplants from donors with a hematologic malignancy and donors with an otorhinolaryngologic cancer history had inferior patient \[hematologic: 7.06 (2.64--18.90) and otorhinolaryngologic: 8.29 (1.17--58.92)\] and graft survival \[hematologic: 6.71 (2.51--17.94) and otorhinolaryngologic: 8.03 (1.13--57.08)\].

Discussion
==========

A severe organ shortage has forced transplant teams to expand donor pools to marginal donors with extended criteria. Donors with malignancy history are marginal donors because they are possibly associated with higher risks than reference donors \[[@b6-medscimonit-24-997],[@b7-medscimonit-24-997]\]. Marginal grafts could be more frequently accepted by patients in critical medical situations or patients who perceive their situation as critical \[[@b8-medscimonit-24-997]\]. In turn, this acceptance may help reduce mortality in those on transplant waiting lists, benefiting the largest number of recipients \[[@b9-medscimonit-24-997]\]. Cancer in donors is considered as a transmissible disease that seriously threatens the recipient's life, which is the main reason why these organs are applied with great caution. Therefore, we should weigh the benefits and threats of transplanted organs from DWCH. Careful evaluation and vigilant screening of potential DWCH can provide valuable data for transplant teams and may identify additional candidates \[[@b10-medscimonit-24-997],[@b11-medscimonit-24-997]\].

In the present study, we found that the number of transplants from DWCH gradually increased yearly. However, we observed no increase in the proportion of DWCH, as they were a low percentage of all donors ([Figure 1C](#f1-medscimonit-24-997){ref-type="fig"}). A total of 4696 (2.24%) kidney transplants and 2713 (3.12%) liver transplants came from DWCH from January 1, 2000 through December 31, 2014 in the SRTR database. NMSC, genitourinary cancer, and CNS cancer were the 3 most frequent cancer types associated with transplants. Notably, liver and heart transplant recipients in the DWCH group had similar outcomes to recipients of these transplants in the ECD group, whereas kidney and lung transplant recipients in the DWCH group had even better outcomes than recipients of these transplants in the ECD group. All these results suggest that DWCH are a qualified source for organ transplantation.

In the literature, attention is always paid to the weaknesses of DWCH, such as DTC. For the first time, we focused on the long-term outcomes of recipients who were transplanted with organs from DWCH in comparison to those receiving organs from DWNCH based on analysis of a nationwide database. In an adjusted survival analysis, the data demonstrated that liver and heart transplant recipients in the DWCH group had lower patient and graft survival than those in the DWNCH group. According to our study, DWCH had the greatest impact on heart transplantation. Recipients of organs from DWCH had lower adjusted 5-year patient survival rates and graft survival rates in heart transplantation, especially for those receiving organs from donors with hematologic malignancy and otorhinolaryngologic cancer. The treatment for these cancers, chemotherapy or radiotherapy, might lead to cardiotoxicity or radioactive myocardial damage \[[@b12-medscimonit-24-997]--[@b14-medscimonit-24-997]\]. Therefore, heart grafts from these donors should be carefully evaluated before their use in heart transplantation.

Our results showed that liver transplantation using organs from DWCH was associated with significantly poorer patient and graft survival. It has been reported that liver transplants from ECD, including DWCH, have comparable outcomes to those from referenced donors \[[@b15-medscimonit-24-997]\]. Even though grafts from DWCH affect overall survival, apparently not all types of cancer are risk factors for survival. A single-center study came to the conclusion that there is no difference in survival between recipients of grafts from donors with CNS tumors and recipients of grafts from donors without CNS tumors in liver transplantation \[[@b16-medscimonit-24-997]\]. Similarly, Warrens et al. showed that life expectancy is not shorter for recipients of a liver from a donor with a primary CNS tumor than for recipients of a liver from a donor without a primary CNS tumor \[[@b17-medscimonit-24-997]\]. However, the present study showed that the graft survival and cancer-free survival of recipients of organs from donors with a CNS cancer history were poorer in liver transplantation than the graft and cancer-free survival of recipients of organs from DWNCH. The reason for this association is largely unknown because we were unable to obtain detailed cancer characteristics from the database. As a result, livers from donors with CNS cancer should be cautiously assessed.

Even though the adjusted 5-year graft survival was a significantly different in kidney transplantation between the 2 groups, this slight difference is worth neglecting owing to the benefit to candidates. Lung transplantation was an exception in that no difference was documented between the 2 groups. These survival analysis results should be provided to transplant candidates for decision-making when organs from DWCH become available.

It is well-known that solid-organ transplant recipients are at increased risk of developing cancer compared with the general population \[[@b18-medscimonit-24-997]\]. In this study, we found that kidney transplant recipients in the DWCH group had a significantly higher incidence of malignancy than those in the DWNCH group. However, after adjustment for potential confounders, the cumulative probability of malignancy was not significantly different in the 4 transplant types. Therefore, under the current practice, the use of organs from DWCH does not increase the long-term incidence of malignancy. Notably, information is absent in the SRTR database concerning whether the malignancy is transmitted, recurrent, or *de novo*. We recommend that these data be added to the SRTR database to better assess the transmission risk of using organs from DWCH.

The current analysis showed comparable outcomes in kidney and lung transplantation using allografts from DWCH versus DWNCH. However, when considering donor cancer type, adjusted hazard assessment suggested that genitourinary and gastrointestinal cancer histories in donors are risk factors for patient and graft survival in kidney transplantation. Carcinogenesis is a multistep process and a multi-systemic disease, indicating that donors with genitourinary and gastrointestinal cancer histories have poorer kidney quality \[[@b19-medscimonit-24-997]\]. Cancer patients experience kidney injury from multiple sources, including the tumor itself, diagnostic procedures, hypovolemia, infection, and drug exposure, which is superimposed upon baseline chronic damage \[[@b20-medscimonit-24-997]\]. It is worth noting that 994 kidney transplants were from donors with a genitourinary cancer history, which represented more than 1/5 of all cancer donors involved in kidney transplantation during the study period. Studies have shown that kidney injury is commonly a frequent and significant complication of cancer and cancer therapy, especially in genitourinary cancers, such as prostate cancer and bladder cancer \[[@b21-medscimonit-24-997]--[@b23-medscimonit-24-997]\]. This tendency in organ allocation should be reevaluated. Moreover, our analysis showed that recipients of organs from donors with a CNS cancer history had equivalent patient and graft survival and better cancer-free survival in kidney transplantation than recipients of organs from DWNCH, which is consistent with the results reported by Tatar et al. in a single-center study \[[@b24-medscimonit-24-997]\].

Although we have provided a comprehensive assessment of how using organs from DWCH affects transplant outcomes, there are some limitations in this study. In the SRTR database, some variables with high missing value rates were excluded from the analysis. The exclusion of these variables might result in selection bias. Moreover, the SRTR database lacks complete documentation of donor cancer history and detailed follow-up of malignancy in recipients, which might lead to underestimates of the incidence of DWCH and development of post-transplant malignancy. Another limitation is that outcomes were not analyzed in pancreas and intestine transplantation due to the small number of DWCH involved in these cases. These limitations call for a well-designed cohort study concerning the use of organs from DWCH to provide high-level evidence for guiding clinical practice.

Conclusions
===========

The current comprehensive analysis of the outcomes suggests that under the current guidelines, DWCH are a qualified source for expanding the donor pool. Organs from DWCH might distinctly affect transplant outcomes in different organ transplant types. Interestingly, transplant outcomes are specifically affected by certain categories of donor cancers in different organ transplantations. Therefore, careful risk and benefit assessments of using organs from DWCH should be made before transplantation. A prospective, multi-center, cohort study is required to provide reliable guidance for clinical practice.

Supplementary Tables
====================

###### 

Donor amount with or without a cancer history from 2000 to 2014 in the SRTR.

  Donor type       Kidney TX   Liver TX   Heart TX   Lung TX   Pancreas TX   Intestine TX   Total
  ---------------- ----------- ---------- ---------- --------- ------------- -------------- --------
  DWCH             4696        2713       504        413       50            9              8385
  DWNCH            209236      86891      33144      21411     6180          2098           372010
  Percentage (%)   2.24        3.12       1.52       1.93      0.81          0.43           2.28

###### 

Clinical characteristics of donors and recipients included in the study.

  Variables                      Kidney transplantation   Liver transplantation   Heart transplantation   Lung transplantation                                                                          
  ------------------------------ ------------------------ ----------------------- ----------------------- ---------------------- --------- ------ ------------ ------- ----- ------------ ------- ----- ------------
  Characteristics of donor                                                                                                                                                                              
  Age                            \<18                     18345                   77                      **\<0.01**             11665     55     **\<0.01**   23787   353   **\<0.01**   2815    11    **\<0.01**
  18--50                         135387                   1767                    48076                   760                    6783      27     15070        213                                      
  \>50                           55504                    2852                    27150                   1898                   2574      124    3526         189                                      
  Gender                         Male                     113302                  1870                    **\<0.01**             51671     1228   **\<0.01**   22979   258   **\<0.01**   12873   161   **\<0.01**
  Female                         95934                    2826                    35220                   1485                   10165     246    8538         252                                      
  Race                           White                    173869                  4396                    **\<0.01**             69660     2507   **\<0.01**   27079   457   **\<0.01**   16470   374   **\<0.01**
  Black                          27680                    230                     14474                   168                    5211      34     3995         27                                       
  Asian                          5498                     44                      1969                    29                     542       7      500          9                                        
  Other/unknown                  2155                     24                      788                     9                      305       6      172          3                                        
  Blood type                     A                        70690                   1761                    **\<0.01**             31739     1009   0.19         11788   211   **0.03**     7634    166   0.30
  B                              22302                    446                     9935                    302                    3468      42     2273         41                                       
  AB                             5693                     120                     2577                    62                     665       10     441          8                                        
  O                              110551                   2369                    42640                   1340                   17223     241    11063        198                                      
  Characteristics of recipient                                                                                                                                                                          
  Age (years)                    \<18                     9783                    68                      **\<0.01**             8034      48     **\<0.01**   9376    129   **\<0.01**   711     7     **0.05**
  18--50                         86848                    1403                    23432                   677                    4964      21     5905         101                                      
  \>50                           112605                   3225                    55425                   2713                   18804     354    14795        305                                      
  Gender                         Male                     127093                  2923                    **0.04**               56555     1801   0.16         23893   348   0.13         12131   222   0.24
  Female                         82143                    1773                    30336                   912                    9251      156    9280         191                                      
  Race                           White                    140790                  3205                    0.55                   73164     2316   0.12         25699   395   0.98         19285   378   0.30
  Black                          53994                    1169                    8853                    244                    6085      89     1718         32                                       
  Asian                          11014                    245                     3800                    126                    956       14     272          1                                        
  Other/unknown                  3426                     77                      1074                    27                     404       6      135          2                                        
  Blood type                     A                        77749                   1837                    **\<0.01**             32354     1071   **\<0.01**   13668   227   0.33         8566    184   0.30
  B                              27150                    535                     11716                   299                    4659      68     2381         45                                       
  AB                             10208                    226                     4317                    124                    1701      21     847          14                                       
  O                              94129                    2098                    38504                   1219                   13116     168    9617         170                                      
  BMI                            \<25                     86774                   1771                    **\<0.01**             31046     825    **\<0.01**   14771   223   0.96         10994   191   0.16
  25--\<30                       63203                    1473                    26445                   863                    10528     162    7071         154                                      
  30--\<35                       39796                    968                     15543                   567                    5436      81     3049         60                                       
  ≥35                            19463                    484                     9164                    316                    1581      27     297          8                                        
  Unknown                        0                        0                       4693                    142                    828       11     0            0                                        
  Primary diagnosis\*            A                        47450                   1183                    **\<0.01**             5013      140    **\<0.01**   27645   453   **0.00**     799     17    0.97
  B                              49590                    1303                    65473                   1999                   1447      22     8280         121                                      
  C                              30353                    598                     11657                   432                    3101      18     7701         150                                      
  D                              80177                    1583                    4748                    142                    951       11     6631         125                                      
  Malignancy history             No                       191219                  4196                    **\<0.01**             78235     1901   0.33         30832   447   **\<0.01**   19717   371   **0.04**
  Yes                            10273                    310                     4259                    144                    1770      45     1259         27                                       
  Unknown                        7310                     184                     1879                    586                    542       12     418          15                                       
  Primary diagnosis\*                                                                                                                                                                                   
                                 A                        Hypertension            ALF                     Cardiomyopathy         Alpha-1                                                                
                                 B                        Diabetes                CLD                     CAD                    COPD                                                                   
                                 C                        GN                      Malignancy              Congenital             IPF                                                                    
                                 D                        Other                   Other                   Other                  Other                                                                  
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![(**A**) The number of transplants from DWCH by year from January 1, 2000, to December 31, 2014. (**B**) Number of transplants from DWCH in different types of organ transplants yearly. (**C**) Proportion of DWCH in all donors by each year.](medscimonit-24-997-g001){#f1-medscimonit-24-997}

![Adjusted patient and graft survival analysis between the two groups of transplantation from donors with or without a cancer history. (**A, E**) Comparison of patient and graft survival in kidney transplant. (**B, F**) Comparison of patient and graft survival in liver transplant. (**C, G**) Comparison of patient and graft survival in heart transplant. (**D, H**) Comparison of patient and graft survival in lung transplant.](medscimonit-24-997-g002){#f2-medscimonit-24-997}

![(**A--D**) The adjusted cumulative probability of cancer after kidney, liver, heart and lung transplant, respectively.](medscimonit-24-997-g003){#f3-medscimonit-24-997}

###### 

Distribution of donor cancer types in various transplants from 2000 to 2014 in the SRTR.

  Cancer type of donor            Kidney TX   Liver TX   Heart TX   Lung TX   Pancreas TX   Intestine TX   Total
  ------------------------------- ----------- ---------- ---------- --------- ------------- -------------- -------
  Non-melanoma skin cancer        1642        898        114        127       4             0              2785
  Melanoma                        183         90         13         12        1             0              299
  Cns cancer                      641         391        180        108       14            3              1337
  Glioblastoma multiforme         106         99         43         22        4             1              275
   Astrocytoma                    135         71         39         13        6             0              264
  Meningioma                      131         71         26         28        4             1              261
   Medulloblastoma                7           9          3          2         0             0              21
  Neuroblastoma                   4           3          2          2         0             0              11
  Angioblastoma                   4           3          0          0         0             0              7
   Tumor -- other                 254         135        67         41        0             1              498
  Genitourinary cancer            994         629        101        72        19            1              1816
   Uterine cervical               546         290        59         35        6             1              937
  Prostate                        113         130        2          9         0             0              254
   Ovarian                        116         68         7          7         1             0              199
   Penis, testicular              68          31         13         3         3             0              118
   Uterine body endometrial       69          38         0          8         0             0              115
   Bladder                        20          21         3          3         8             0              55
  Kidney                          9           24         5          4         1             0              43
   Vulva                          19          7          1          1         0             0              28
   Uterine body choriocarcinoma   10          5          7          1         0             0              23
  Genitourinary, unknown          24          15         4          1         0             0              44
  Breast cancer                   295         165        7          13        1             0              481
  Thyroid cancer                  125         51         4          11        0             0              191
  Hematologic malignancy          59          36         5          6         0             0              106
  Gastrointestinal cancer         80          59         5          7         0             0              151
  Colo-rectal                     61          48         4          5         0             0              118
  Stomach                         4           7          1          2         0             0              14
  Small intestine                 5           4          0          0         0             0              9
  Pancreas                        6           0          0          0         0             0              6
   Esophageal                     2           0          0          0         0             0              2
  Liver/biliary tract             2           0          0          0         0             0              2
  Lung cancer                     15          15         0          0         0             0              30
  Otorhinolaryngologic cancer     30          29         1          2         0             0              62
  Tongue/throat                   21          21         0          0         0             0              42
  Larynx                          9           8          1          2         0             0              20
  Other, specify                  632         350        74         55        11            5              1127
  Total                           4696        2713       504        413       50            9              8385

###### 

Survival outcomes of transplants from DWCH versus ECD.

  TX type   5-year patient survival rate   5-year graft survival rate   10-year cancer-free survival rate                                        
  --------- ------------------------------ ---------------------------- ----------------------------------- ----- ----- ------------ ----- ----- ----------
  Kidney    75%                            82%                          **\<0.01**                          62%   72%   **\<0.01**   80%   82%   **0.03**
  Liver     66%                            66%                          0.86                                62%   61%   0.26         50%   48%   0.25
  Heart     68%                            69%                          0.97                                67%   68%   0.95         67%   70%   0.37
  Lung      50%                            56%                          **0.04**                            47%   54%   **0.04**     42%   43%   0.25

DWCH -- donors with a cancer history; ECD -- expanded criteria donor, TX -- treatment

###### 

Malignancy cases identified at follow-up in recipients from DWCH.

  TX type   Following years   Observed cases   Expected cases   OR           95% CI       P
  --------- ----------------- ---------------- ---------------- ------------ ------------ ----------
  Kidney    5                 285              245.13           1.18         1.04--1.33   **0.01**
  10        397               353.28           1.14             1.03--1.26   **0.01**     
  Liver     5                 223              208.84           1.12         0.96--1.30   0.15
  10        284               282.16           1.11             0.96--1.27   0.11         
  Heart     5                 46               42.75            1.16         0.86--1.57   0.32
  10        75                67.76            1.13             0.88--1.44   0.34         
  Lung      5                 43               54.47            0.79         0.58--1.09   0.15
  10        71                75.64            0.97             0.75--1.25   0.79         

DWCH -- donors with a cancer history; TX -- treatment; OR -- odds ratio; 95% CI -- 95% confidence interval.

###### 

Overall hazard assessment of donor cancer type on recipient survival.

  Donor cancer types             Patient survival   Graft survival   Cancer-free survival                                                        
  ------------------------------ ------------------ ---------------- ---------------------- ------ ------------- ---------- ------ ------------- ----------
  Kidney transplantation                                                                                                                         
   No cancer                     1.00               --               --                     1.00   --            --         1.00   --            --
   CNS cancer                    1.18               0.99--1.40       0.06                   1.14   1.00--1.30    0.06       0.67   0.49--0.93    **0.02**
   Non-melanoma skin cancer      1.09               0.98--1.22       0.11                   1.04   0.96--1.14    0.34       1.22   1.05--1.42    **0.01**
   Melanoma                      1.09               0.81--1.47       0.57                   0.96   0.75--1.23    0.75       0.79   0.47--1.31    0.35
   Genitourinary cancer          1.20               1.04--1.38       **0.01**               1.25   1.13--1.39    **0.00**   0.92   0.73--1.16    0.47
   Thyroid cancer                1.00               0.65--1.55       1.00                   0.89   0.621.26      0.51       1.41   0.82--2.44    0.21
   Hematologic malignancy        0.89               0.45--1.78       0.74                   1.22   0.78--1.92    0.38       0.00   --            0.56
   Lung cancer                   2.54               1.06--6.10       **0.04**               1.78   0.80--3.96    0.16       1.29   0.18--9.16    0.80
   Otorhinolaryngologic cancer   0.67               0.28--1.60       0.37                   0.56   0.27--1.17    0.12       0.98   0.32--3.05    0.98
   Breast cancer                 0.96               0.73--1.26       0.76                   1.03   0.84--1.26    0.80       0.93   0.621.41      0.75
   Gastrointestinal cancer       1.70               1.13--2.56       **0.01**               1.55   1.12--2.15    **0.01**   0.92   0.41--2.05    0.84
   Other, specify                1.03               0.86--1.23       0.77                   0.96   0.83--1.11    0.59       0.99   0.76--1.29    0.94
  Liver transplantation                                                                                                                          
   No cancer                     1.00               --               --                     1.00   --            --         1.00   --            --
   CNS cancer                    1.19               0.98--1.45       0.08                   1.23   1.03--1.46    **0.02**   1.36   1.01--1.83    **0.05**
   Non-melanoma skin cancer      1.10               0.97--1.25       0.14                   1.14   1.02--1.28    **0.02**   1.19   0.96--1.46    0.11
   Melanoma                      1.22               0.83--1.79       0.32                   1.21   0.85--1.71    0.29       0.67   0.28--1.60    0.36
   Genitourinary cancer          1.01               0.86--1.19       0.86                   1.07   0.93--1.23    0.33       1.38   1.09--1.74    **0.01**
   Thyroid cancer                1.12               0.65--1.93       0.69                   1.25   0.79--1.99    0.34       1.31   0.59--2.93    0.50
   Hematologic malignancy        1.57               0.89--2.77       0.12                   1.51   0.90--2.55    0.12       1.81   0.73--4.34    0.19
   Lung cancer                   1.04               0.39--2.76       0.94                   1.05   0.44--2.52    0.92       2.08   0.67--6.46    0.20
   Otorhinolaryngologic cancer   1.22               0.63--2.34       0.56                   1.21   0.67--2.19    0.52       1.60   0.60--4.26    0.35
   Breast cancer                 0.96               0.70--1.32       0.78                   1.06   0.81--1.38    0.69       1.51   0.97--2.34    0.07
   Gastrointestinal cancer       0.51               0.26--1.02       0.06                   1.45   0.24--1.87    0.52       1.04   0.43--2.49    0.94
   Other, specify                1.14               0.93--1.40       0.21                   1.18   0.98--1.41    0.08       0.98   0.48--1.42    0.92
  Heart transplantation                                                                                                                          
   No cancer                     1.00               --               --                     1.00   --            --         1.00   --            --
   CNS cancer                    1.21               0.91--1.62       0.19                   1.20   0.91--1.60    0.20       1.11   0.78--1.59    0.56
   Non-melanoma skin cancer      1.17               0.82--1.66       0.40                   1.19   0.84--1.68    0.33       1.11   0.71--1.74    0.65
   Melanoma                      1.24               0.47--3.31       0.67                   1.18   0.44--3.16    0.74       0.91   0.23--3.65    0.90
   Genitourinary cancer          1.29               0.88--1.90       0.20                   1.24   0.84--1.82    0.28       0.65   0.35--1.21    0.17
   Thyroid cancer                1.15               0.168.16         0.89                   1.10   0.16--7.85    0.92       7.73   1.92--31.04   **0.00**
   Hematologic malignancy        7.06               2.64--18.90      **0.00**               6.71   2.51--17.94   **0.00**   0.00   --            0.93
   Otorhinolaryngologic cancer   8.29               1.17--58.92      **0.03**               8.03   1.13--57.08   **0.04**   0.00   --            1.00
   Breast cancer                 2.81               0.91--8.72       0.07                   2.67   0.86--8.29    0.09       0.00   --            0.91
   Gastrointestinal cancer       2.29               0.57--9.18       0.24                   2.20   0.558.82      0.26       0.00   --            0.92
   Other, specify                1.14               0.72--1.81       0.59                   1.08   0.681.72      0.73       1.11   0.63--1.96    0.71

HR -- hazard ratio; 95% CI -- 95% confidence interval.
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